1. Home
  2. RELI vs CHRO Comparison

RELI vs CHRO Comparison

Compare RELI & CHRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RELI
  • CHRO
  • Stock Information
  • Founded
  • RELI 2013
  • CHRO 2002
  • Country
  • RELI United States
  • CHRO United States
  • Employees
  • RELI N/A
  • CHRO N/A
  • Industry
  • RELI Specialty Insurers
  • CHRO
  • Sector
  • RELI Finance
  • CHRO
  • Exchange
  • RELI Nasdaq
  • CHRO Nasdaq
  • Market Cap
  • RELI 3.3M
  • CHRO 3.8M
  • IPO Year
  • RELI N/A
  • CHRO 2024
  • Fundamental
  • Price
  • RELI $2.14
  • CHRO $1.90
  • Analyst Decision
  • RELI Strong Buy
  • CHRO Strong Buy
  • Analyst Count
  • RELI 1
  • CHRO 1
  • Target Price
  • RELI $119.00
  • CHRO N/A
  • AVG Volume (30 Days)
  • RELI 5.6M
  • CHRO 855.2K
  • Earning Date
  • RELI 11-07-2024
  • CHRO 02-20-2025
  • Dividend Yield
  • RELI N/A
  • CHRO N/A
  • EPS Growth
  • RELI N/A
  • CHRO N/A
  • EPS
  • RELI N/A
  • CHRO N/A
  • Revenue
  • RELI $14,078,473.00
  • CHRO N/A
  • Revenue This Year
  • RELI N/A
  • CHRO N/A
  • Revenue Next Year
  • RELI N/A
  • CHRO N/A
  • P/E Ratio
  • RELI N/A
  • CHRO N/A
  • Revenue Growth
  • RELI 4.71
  • CHRO N/A
  • 52 Week Low
  • RELI $1.18
  • CHRO $0.45
  • 52 Week High
  • RELI $18.53
  • CHRO $6.00
  • Technical
  • Relative Strength Index (RSI)
  • RELI 49.98
  • CHRO 86.63
  • Support Level
  • RELI $1.73
  • CHRO $0.81
  • Resistance Level
  • RELI $2.50
  • CHRO $1.10
  • Average True Range (ATR)
  • RELI 0.41
  • CHRO 0.26
  • MACD
  • RELI -0.07
  • CHRO 0.08
  • Stochastic Oscillator
  • RELI 27.33
  • CHRO 70.64

About RELI Reliance Global Group Inc.

Reliance Global Group Inc operates as a holding company with diversified interests in the insurance market, as well as other related sectors. The company focuses on growing by pursuing an acquisition strategy, initially and primarily focused on wholesale and retail insurance agencies. Its primary strategy is to identify specific risks to reward arbitrage opportunities and develop these on a national platform, thereby increasing revenues and returns, and then identify and acquire undervalued wholesale and retail insurance agencies with operations in growing or underserved segments, expand and optimize their operations, and achieve asset value appreciation while generating interim cash flows. The company generates revenue in the form of commissions.

About CHRO Chromocell Therapeutics Corporation

Channel Therapeutics Corp is a clinical-stage biotechnology company developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain. The initial clinical focus is to selectively target the sodium ion channel known as NaV1.7 for the treatment of various types of chronic pain, acute and chronic eye pain, and post-surgical nerve blocks. Its pipeline includes CC8464 for ISFN and EM and CT2000 for Acute and CHronic Eye Pain-Dry Eye Disease.

Share on Social Networks: